By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – San Diego-based startup molecular diagnostics firm NexDx today said it has finalized a deal with the University of California, San Diego to develop and commercialize epigenetic biomarkers targeting rheumatoid arthritis.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.